Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Eton Pharmaceuticals (ETON) Shares Outstanding (2017 - 2025)

Eton Pharmaceuticals' Shares Outstanding history spans 8 years, with the latest figure at $27.0 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 1.27% to $27.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $27.0 million, a 1.27% increase, with the full-year FY2025 number at $27.0 million, up 1.27% from a year prior.
  • Shares Outstanding hit $27.0 million in Q4 2025 for Eton Pharmaceuticals, up from $26.8 million in the prior quarter.
  • Over the last five years, Shares Outstanding for ETON hit a ceiling of $25.7 billion in Q1 2024 and a floor of $24.5 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $1.3 billion across 5 years, with a median of $25.6 million in 2023.
  • Biggest five-year swings in Shares Outstanding: soared 100630.01% in 2024 and later plummeted 99.9% in 2025.
  • Tracing ETON's Shares Outstanding over 5 years: stood at $24.6 million in 2021, then increased by 2.95% to $25.4 million in 2022, then rose by 1.32% to $25.7 million in 2023, then rose by 3.97% to $26.7 million in 2024, then grew by 1.27% to $27.0 million in 2025.
  • Business Quant data shows Shares Outstanding for ETON at $27.0 million in Q4 2025, $26.8 million in Q3 2025, and $26.8 million in Q2 2025.